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a  b  s  t  r  a  c  t
A  number  of  small  molecule  tyrosine  kinase  inhibitors  (TKIs)  have  now  been  approved  for the  treatment  of
non-small  cell  lung  cancers  (NSCLC),  including  those  targeted  against  epidermal  growth  factor  receptor,
anaplastic  lymphoma  kinase,  and  ROS1.  Despite  a wealth  of  agents  developed  to target  the receptor
tyrosine  kinase,  MET,  clinical  outcomes  have  as  yet  been  disappointing,  leading  to  pessimism  about  the
role of MET  in  the  pathogenesis  of  NSCLC.  However,  in  recent  years,  there  has  been a renewed  interest
in  MET  exon  14  alterations  as  potential  drivers  of  lung cancer.
MET  exon  14 alterations,  which  result  in  increased  MET  protein  levels  due to  disrupted  ubiquitin-
mediated  degradation,  occur  at a prevalence  of  around  3% in  adenocarcinomas  and around  2%  in  other  lung
neoplasms,  making  them  attractive  targets  for the  treatment  of lung  cancer.  At least  ﬁve  MET-targeted
TKIs,  including  crizotinib,  cabozantinib,  capmatinib,  tepotinib,  and  glesatinib,  are  being  investigated  clin-
ically  for  patients  with  MET  exon  14  altered-NSCLC.  A further  two  compounds  have  shown  activity  in
preclinical  models.  In this  article,  we  review  the  current  clinical  and  preclinical  data  available  for  these
TKIs,  along  with  a number  of  other  potential  therapeutic  options,  including  antibodies  and  immunother-
apy.  A number  of  questions  remain  unanswered  regarding  the  future  of  MET  TKIs,  but unfortunately,  the
development  of  resistance  to targeted  therapies  is  inevitable.  Resistance  is expected  to arise  as a  result
of receptor  tyrosine  kinase  mutation  or from  upregulation  of  MET  ligand  expression;  potential  strategies
to  overcome  resistance  are  proposed.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction (the Why)
Orally available small molecule tyrosine kinase inhibitors (TKIs)
ave now been approved for epidermal growth factor receptor
EGFR)-mutated, anaplastic lymphoma kinase (ALK)-rearranged,
nd ROS1-rearranged non-small cell lung cancers (NSCLC), altering
he treatment landscape of NSCLC [1]. Alterations (point mutations,
mpliﬁcations, protein overexpression, and fusions) in another
eceptor tyrosine kinase (RTK), the hepatocyte growth factor (HGF)
eceptor (MET), have been identiﬁed in NSCLC, and a plethora of
ET-targeted agents (small molecular TKIs and antibodies against
GF or MET) have been investigated in this disease type [2]. Disap-
ointingly, despite the wide spectrum of MET  alterations in NSCLC,
andomized trials with MET  inhibitors have not resulted in clinical
eneﬁt [3–5]. These disappointing results have led to pessimism
bout the role of MET  in the pathogenesis of NSCLC and the validity
f MET  as a targetable driver in NSCLC. This review will concentrate
n the recent re-emergence of MET  exon 14 (METex14) splicing
lterations in NSCLC that has led to renewed optimism of METex14
lteration as a targetable mutation that may  lead to the approval
f MET-speciﬁc inhibitors in NSCLC.
.1. METex14 splicing mutations in NSCLC
The MET  signaling pathway has recently been reviewed in detail
6]. The timeline of events leading to the recognition of METex14
lteration as an important driver in lung cancer is summarized in
ig. 1. In 1994, an alternatively spliced MET  RTK with deletion of
he 47-amino acid juxtamembrane region of the MET  receptor was
eported [7], followed by the demonstration that mutation of a
yrosine residue at position 1001 in this juxtamembrane region
ed to a partial gain of function [8]. In 2001, Peschard and col-
eagues reported that mutation of tyrosine residue 1003 in the
inding domain of the E3 ubiquitin-protein ligase, c-CBL, abolished
-CBL binding to MET, disrupting c-CBL-mediated degradation and
eading to MET  oncogenic activity [9]. Y1003 is located in the
uxtamembrane region of MET  and is encoded by exon 14 [6]. Sub-
equently, mutations in the METex14 splice sites were reported by
a and colleagues in small cell lung cancer in 2003 and NSCLC
n 2005 [10,11]. The signiﬁcance of these splice site mutations
as further characterized by Kong-Beltran and colleagues in 2006,
hen they identiﬁed both single nucleotide substitutions and small . . .  . .  . . . . .  . . . .  . . . .  . . .  . . .  . . .  .  .  . . .  . . . .  .  . . . . . . .  . . . . .  .  . . .  . . . . . .  .  . .  .  .  .  .  . . . .  . . .  . . . 35
deletions in the 5′ and 3′ splice sites around METex14 in lung
tumor samples, and demonstrated that these mutations resulted
in METex14 skipping. The exon 14-spliced protein had abolished
c-CBL E3 ligase binding, resulting in decreased ubiquitination,
and leading to a relative increase in MET  protein levels. Addi-
tionally, MET  Y1003 mutation was  shown to result in decreased
ubiquitination and increased stability of the MET  protein. Both
METex14-spliced and MET  Y1003-mutated proteins were trans-
forming in vitro and in a xenograft model that was inhibited by
an anti-MET antibody [12]. Since then, sporadic case series have
reported the incidence of METex14 alterations in NSCLC to be
around 2–4% [13–15]. It was  not until 2015 that large scale molec-
ular proﬁling of METex14 alterations in 38,028 tumor samples
by Frampton and colleagues led to renewed focus on METex14
alterations in lung carcinomas [16]. Among the 221 tumor sam-
ples harboring METex14 alterations, 193 were in lung carcinomas,
including 131 lung adenocarcinoma samples. No other common
solid tumor malignancies harbored METex14 alterations to the
same degree as lung neoplasms [16]. Furthermore, in 2015, an
in vitro model using the CRISPR/Cas9 system in HEK293 cell lines
demonstrated that METex14 deletion resulted in higher MET  pro-
tein expression levels, enhanced MET  phosphorylation, prolonged
MET activation, and enhanced cellular growth, colony forma-
tion, and MET  inhibitor sensitivity [17]. Contemporaneously, case
reports and case series have reported that patients with METex14
altered NSCLC (METex14+ NSCLC) respond to MET  TKIs [18–22].
Since late 2015, reports characterizing patients with METex14+
NSCLC have been published in rapid succession in the literature
(Table 1) [16,23–31]. To date, it can be summarized that METex14
alterations are found in a relatively elderly population of patients
with NSCLC, and are enriched in sarcomatoid histologies, with a
prevalence ranging from 8 to 22% [25,31]. On average, METex14
alterations occurred at a prevalence of about 3% in lung adeno-
carcinoma, and notably, at a prevalence of slightly higher than
2% in squamous cell carcinoma (SqCC) [31]. Available data on the
overlap between METex14 alterations, MET ampliﬁcation, and MET
point mutations are sparse, but concurrent MET  ampliﬁcation has
been reported in 15–21% of METex14+ NSCLC [24,26,31], and MET
Y1003X mutations account for around 2% of the METex14 alter-
ations in NSCLC [31]. Based on 28 patients, Awad and colleagues
showed that Stage IV METex14–mutated NSCLCs were signiﬁcantly
more likely to have concurrent MET genomic ampliﬁcation and
T. Reungwetwattana et al. / Lung Cancer 103 (2017) 27–37 29
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aig. 1. Timeline of the emergence of MET  exon14 skipping alterations in NSCLC.
ETex14: MET  exon 14; NSCLC: non-small cell lung cancer; TCGA: The Cancer Geno
trong MET  immunohistochemical expression than stage IA to IIIB
ETex14–mutated NSCLCs [24]. However, a much larger series of
98 METex14+ patients did not show the correlation between MET
mpliﬁcation and advanced stage [31].
. Clinical trial design considerations of a MET  TKI trial
argeting METex14+ NSCLC (the How)
There are several MET  TKIs in development that target
ETex14+ NSCLC, and completing accrual as soon as possible is
f paramount importance given the relatively low incidence of
ETex14+ NSCLC. Eligibility criteria for MET  TKI trials in METex14+
SCLC should thus be tailored to allow speedy accrual. From the
eport of Schrock and colleagues, METex14 alterations occur in
pproximately 2% of patients with SqCC [31], and these patients
ave been shown to respond to MET  TKIs [16,27,31]. Therefore, it
s advised to include both major histologies (adenocarcinoma and
qCC) in addition to sarcomatoid lung cancer.
It is generally accepted that in NSCLC with a validated targetable
river mutation, highly effective targeted therapy should work
egardless of prior lines of chemotherapy. For example, a phase
 study of crizotinib in ROS1 inhibitor-naïve ROS1+ NSCLC patients
evealed no difference in the overall response rate (ORR) whether
atients were treatment naïve or had received more than three
rior chemotherapy regimens [32]. Thus, a clinical trial of MET  TKIs
n METex14+ NSCLC patients should allow any prior lines of therapy
chemotherapy or immunotherapy). Indeed, the recently presented
hase 2 trial of crizotinib in METex14+ NSCLC patients allowed both
reatment-naïve and chemotherapy-refractory patients [33].
Finally, a sensitive, reliable, and rapid molecular test that can be
asily performed in diagnostics laboratories should be incorporated
nto MET  TKI trials, for the purpose of getting a compendium of
iagnostics for METex14 alterations approved. As shown in Table 1,
ost of the methods used to detect METex14 alterations, includ-
ng MET  Y1003 mutation, are based on DNA sequencing. Thus, the
ctual results of METex14 skipping are inferred from the substitu-tlas; TKI: tyrosine kinase inhibitor.
tions and indels observed at the splice donor and acceptor sites. As
demonstrated by The Cancer Genome Atlas (TCGA) analysis of ade-
nocarcinoma, some of the METex14 alterations detected at the DNA
level resulted in incomplete (80%) METex14 skipping [14]. Thus,
conﬁrmation of actual METex14 skipping by differential MET exon
expression [15,21], quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) [24], or direct RNA sequencing [15,27]
should be part of the test for METex14 alterations. Additionally,
both DNA and RNA sequencing methods will be needed to detect
Y1003, the “functional analog” of METex14 skipping alterations,
which accounts for approximately 2% of all METex14 alterations
[31].
3. MET  TKI in METex14 skipping alterations in NSCLC (the
Who)
Multiple MET  inhibitors, including both small molecule TKIs
and monoclonal antibodies (mAbs) against MET  or its ligand, HGF,
have been in clinical development since the early 2000 s [34]. TKIs
can generally be divided into three types (I, II, and III) [35,36].
The binding of ATP to the MET  kinase domain has been suc-
cinctly reviewed by Gherardi and colleagues [35]. The apo-MET
kinase adopts a unique autoinhibitory conformation with the acti-
vation loop locked into the ATP triphosphate binding site via a
salt bridge between D1228 and K1110. Type I MET-inhibitors are
ATP-competitive, and bind to this MET  unique autoinhibitory con-
formation with characteristic interaction (-stacking) with Y1230
in the MET  activation loop. Type I inhibitors can be further divided
into two  types: type Ia and type Ib. The potency of type Ia inhibitors
comes from interaction with Y1230, the hinge, and the solvent
front glycine residue G1163 (analogous to the same position as
ALK G1202 and ROS1 G2032), whereas type Ib series have stronger
interactions with Y1230 and the hinge, but normally no interac-
tion with G1163. Type Ib inhibitors are highly speciﬁc for MET  with
fewer off target effects as compared with type Ia inhibitors.
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Table 1
Studies reporting the clinicopathologic characteristics of MET  exon 14 skipping alterations.
Study Histology
studied
Region Diagnostic
method
Concurrent
MET
ampliﬁcation
Concurrent
genomic
alterations
reported
Prevalence
Okuda et al, 2008 [76] All NSCLC
histologies
Nagoya, Japan Sanger
sequencing
No Not reported 1.7% (3/178)
Onozato et al, 2009 [13] All NSCLC
histologies
(211 adenocar-
cinoma)
Nagoya, Japan RT-PCR
followed by
genomic
sequencing
No Not reported 3.3% (7/211) adenocarcinoma
Seo  et al, 2012 [14] Adenocarcinoma Seoul, Republic
of Korea
RNA
sequencing
(transcriptome
sequencing)
No Not reported 3.4% (3/87)
TCGA,  2014 [15] Adenocarcinoma USA WES  Not tested Not reported 4.3% (10/230)
Frampton et al, 2015 [16] All histologies USA Hybrid capture
NGS
Not reported MDM2
ampliﬁcation;
CDK4
ampliﬁcation
3% (131/4402)
adenocarcinoma; 2.3%
(62/2669) other lung
histologies
Park  et al, 2015 [23] Adenocarcinoma Seoul, Republic
of Korea
RT-PCR
followed by
genomic DNA
sequencing
No Not reported 2.9% (2/70)
Awad  et al, 2016 [24] All NSCLC
histologies
Boston, USA NGS,
conﬁrmation
by qRT-PCR
21% 46% MDM2
ampliﬁcation
3% (28/933) non-squamous
NSCLC; 0% (0/132) squamous
cell carcinoma
Liu  et al, 2016 [25] Pulmonary
sarcomatoid
carcinoma
New York, USA WES, RT-PCR
followed by
conﬁrmation
by Sanger
sequencing
Not tested Not reported 22.2% (8/36)
Tong  et al, 2016 [26] All NSCLC
histologies
Hong Kong,
China
PCR-Sanger
sequencing
33.3% Not reported 2.6% (10/392) adenocarcinoma;
4.8% (1/21) adenosquamous
cell; 31.8% (7/22) pulmonary
sarcomatoid carcinoma; 0%
(0/180) squamous carcinoma;
0% (0/45) large cell carcinoma
Heist et al, 2016 [27] All histologies Boston, USA Anchored
multiplex RNA
sequencing,
conﬁrmed by
DNA
sequencing
1/16 with
borderline MET
ampliﬁcation
Not reported 19% (10/54) of the enriched
cohort (wild-type EGFR, KRAS,
BRAF, ERBB2,  ALK, and ROS1);
5.6% (5/89) of clinical samples
Saito  et al, 2016 [28] Adenocarcinoma Tokyo, Japan RNA
sequencing*
No Not reported 2.8% (9/319)
Zheng et al, 2016 [29] All NSCLC
histologies
Shanghai,
China
qRT-PCR Not tested Not reported 1.6% (21/1305)
adenocarcinoma;
4.2% (2/48) adenosquamous;
0% (0/417) squamous cell
carcinoma
Liu  et al, 2016 [30] All NSCLC
histologies
Guangdong,
China
NGS, Sanger
sequencing
No Not reported 0.9% (10/1101)
adenocarcinoma; 5% (1/20)
squamous cell; 0.7% (1/136)
adenosquamous cell carcinoma
Schrock  et al, 2016 [31] All histologies USA Hybrid capture
NGS
14.8% 34.6% MDM2
ampliﬁcation;
21.1% CDK4
ampliﬁcation;
6.4% EGFR
ampliﬁcation
2.8% (205/7140)
adenocarcinoma; 2.1%
(25/1206) squamous cell
carcinoma; 8.2% (8/98)
adenosquamous carcinoma;
7.7% (8/107) sarcomatoid
carcinoma; 3.0% (49/1659) NOS
Halmos  et al, 2016 [99] All NSCLC USA Hybrid capture
based
comprehensive
genomic
proﬁling
Not reported Not reported 11.5% (16/139) lung
sarcomatoid carcinoma; 2.8%
other NSCLC
ALK: anaplastic lymphoma kinase; CDK4: cyclin-dependent kinase 4; EGFR: epidermal growth factor receptor; MDM2:  Mouse double minute 2 homolog; NGS: next-
g ncer;
w
a
s
ceneration sequencing; NOS: not otherwise speciﬁed; NSCLC: non-small cell lung ca
hole-exome sequencing.
* Based on Sunami et al., 2016 [100].Type II inhibitors are also ATP-competitive, but bind to the ATP
denine binding site and extend to the hydrophobic back pocket. As
uch, type II inhibitors generally distort the apo-MET autoinhibitory
onformation and bind to an induced conformation with a certain qRT-PCR, quantitative RT-PCR; RT-PCR: real-time polymerase chain reaction; WES,penalty; potency depends on the activation state of the MET  pro-
tein. Normally, there is no interaction with the solvent front residue
G1163; thus, type II inhibitors could potentially rescue solvent front
mutations. However, as type II inhibitors occupy the induced back
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Table  2
Tyrosine kinase inhibitors targeting MET  exon 14 skipping alterations.
Compound Company Targets Type of
inhibitor
Enzyme
IC50, nM
Cellular IC50
(cell line), nM
Clinicaltrials.gov NCT
number/EuDraCT number
Crizotinib [39,83] Pﬁzer MET, ALK,
ROS1
Type Ia <1.0 8; 8.6 ± 2
(A549)
NCT00585195
(PROFILE-1001)
NCT02465060 (NCI-MATCH)
NCT02499614 (METROS)
NCT02664935 (Matrix)
Capmatinib [47] Novartis MET  Type Ib 0.13 0.4 (H596);*
0.7 (A549)
NCT02750215
NCT01324479
Tepotinib [51] Merck MET  Type Ib 3 9 (EBC-1) NCT02864992/2015-005696-
24
Savolitinib [54,57] AstraZeneca/Hutchison
China Meditech
MET Type Ib 5 4 (H1993) NCT02897479
AMG337 [58] Amgen/Nanbio MET  Type Ib 1 No current clinical trials;
in vitro activity against
METex14+ gastric cell line
(Hs746T)
Cabozantinib [61] Elexis MET,
VEGFR2,
RET, KIT,
TIE-2, AXL
Type II 1.3 7.8 (PC3) NCT01639508
Glesatinib [67] Mirati
Therapeutics
MET, VEGFR,
RON, TIE-2
Type II 1 20 (MKN45) NCT02544633
Merestinib [70] Lilly MET, TIE-1,
AXL, ROS1,
DDR1/2,
FLT3, MERTK,
RON,
MKNK1/2
Type II 4.7 35 (H460);
52 (S114)
NCT02920996
ALK: anaplastic lymphoma kinase; DDR1/2: discoidin domain receptor tyrosine kinase 1/2; EGFR: epidermal growth factor receptor; FLT-3: FMS-like tyrosine kinase-3; IC50:
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* H596 is a NSCLC cell line that harbors METex14 deletions.
ocket with high energy, clinically, it is easy to develop resistance
rom a free energy point if MET  is activated by HGF [37]. Type III
nhibitors bind to allosteric sites distinct from the ATP binding site
35]; currently there are no type III inhibitors being tested in clin-
cal trials for oncology. Type I and II MET  TKIs in development in
ETex14+ NSCLC are shown in Table 2.
.1. Type Ia inhibitors
.1.1. Crizotinib (Xalkori, PF-02341066)
Crizotinib (PF-02341066, Xalkori; developed by Pﬁzer) is an
rally available, ATP-competitive, type I inhibitor, with potent
nhibitory activity against MET  (half inhibitory concentration [IC50],
–11 nM), ALK (IC50, 24–60 nM), and ROS1 (IC50, 55 nM)  [38–40].
n MET-dependent cancer cell lines, crizotinib inhibits autophos-
horylation of MET, which in turn leads to inhibition of signal
ransduction and cell proliferation, and induction of apoptosis
38,41].
In August 2011, crizotinib was approved for the treatment of
LK-rearranged NSCLC [42], and in March 2016, was approved for
reatment of ROS1-rearranged NSCLC by the US Food and Drug
dministration (FDA) [43]. Crizotinib has also demonstrated clin-
cal activity in NSCLC with MET  ampliﬁcation, especially among
atients with high MET  ampliﬁcation, proving it is a bona ﬁde
ET inhibitor [40,44]. Preliminary results were recently presented
rom the PROFILE-1001 study in which 21 treatment-naïve or
hemotherapy-refractory METex14+ NSCLC patients were enrolled,
8 of which were evaluable at the time of presentation. Within a rel-
tively short 5.3 months of median follow-up time, the ORR was  44%
33]. Additionally, crizotinib is the TKI for the METex14 arms of two
arge phase 2 basket trials; the NCI-MATCH trial (NCT02465060) in
he US and the National Lung Matrix trial (NCT02664935) in the
K, for patients with METex14+ solid malignancies and lung cancer
espectively [45,46]. A phase 2 trial, the METROS study, is ongo-nase-interacting serine/threonine-protein kinase 1/2; NSCLC: non-small cell lung
ing in pretreated patients with metastatic NSCLC with MET  or ROS
aberrations (Table 2) [45]. With the safety data of crizotinib ﬁrmly
established, it is likely that crizotinib will be the ﬁrst MET  TKI to
receive FDA approval for METex14+ NSCLC in the near future.
3.2. Type Ib inhibitors
3.2.1. Capmatinib (INC280)
Capmatinib (INC280; Novartis) is also an oral, ATP-competitive,
type Ib MET  inhibitor. It has extremely potent inhibitory activ-
ity against MET, with a cellular kinase IC50 of 0.13 nM,  and a
cell-based IC50 of 0.4–0.7 nM (Table 1) [47]. Capmatinib inhibits
signaling pathways and cell proliferation, induces apoptosis in
MET-dependent cell lines, and demonstrates single-agent anti-
tumor activity in MET-driven mouse xenograft models [47]. The
efﬁcacy and safety of capmatinib as a single agent were investigated
in a phase 1 study in patients with advanced solid tumors, including
a cohort of EGFR-wild-type MET+ (mutated, ampliﬁed, or rear-
ranged) NSCLC patients (N = 55). The drug was  well tolerated, with
no grade 3/4 adverse events occurring in over 10% of patients, and
preliminary activity was observed in NSCLC patients with high MET
gene copy number (GCN) ≥6 or MET  overexpression as measured
by immunohistochemistry (IHC 3 +), with an ORR of 47% and 24%,
respectively [48]. Four METex14+ NSCLC patients were enrolled and
all achieved signiﬁcant reductions in tumor volume (>45%) [22,48].
A phase 2 trial of capmatinib that includes a study arm investigating
its clinical efﬁcacy in METex14+ NSCLC patients is currently ongoing
(GEOMETRY mono-1) [45]. There is also an investigator-initiated
phase 2 study of capmatinib in patients with METex14+ NSCLC who
have received a prior MET  inhibitor (Table 2) [45]. Furthermore,
capmatinib has been investigated in combination with geﬁtinib in
patients with EGFR-mutated NSCLC, and acquired MET  ampliﬁca-
tion as a resistance mechanism to EGFR inhibitors; the ORR was
50% in patients with MET GCN ≥6 [49]. A phase 2 study (GEOME-
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RY duo-1) is ongoing for this clinical setting, in combination with
rlotinib [50].
.2.2. Tepotinib (MSC2156119J, EMD  1214063)
Tepotinib (EMD1214063, MSC2156119J; Merck) is another
ral, ATP-competitive, and highly selective MET  inhibitor [51].
reclinical antitumor activity was observed in a number of
urine xenograft models of human tumors, including in the
igand-independent, MET-ampliﬁed EBC-1 NSCLC model. Antitu-
or  activity was also seen in other non-lung tumor models,
egardless of whether MET  activation was HGF dependent or inde-
endent [51].
The efﬁcacy and safety of tepotinib was assessed in a phase 1
ingle-agent study in patients with solid tumors, including NSCLC.
epotinib was well tolerated and showed antitumor activity, espe-
ially in patients with overexpressed or ampliﬁed MET  [52]. A phase
 trial investigating the activity of tepotinib in METex14+ NSCLC
atients has been initiated (Table 2) [45,53]
.2.3. Savolitinib (AZD6094, volitinib, HMPL-504)
Savolitinib (AZD6094, volitinib, HMPL-504; AstraZeneca) is an
rally available inhibitor, with potent, selective activity against
ET [54]. In preclinical studies, savolitinib inhibited phosphoryla-
ion of MET  and downstream signaling, and had antitumor activity
gainst a number of xenograft models, including those of EGFR- and
RAS-wild-type NSCLC [55]. The safety and efﬁcacy of savolitinib as
 single agent was investigated in a phase 1 study in patients with
olid tumors, including NSCLC. The drug was well tolerated, and
reliminary antitumor activity was observed [56]. Savolitinib has
lso demonstrated inhibitory activity against METex14 alterations
nd MET  Y1003 mutations in cell lines with acquired resistance to
avolitinib mediated by MYC  overexpression [57]. A phase 2 trial
f savolitinib in patients with METex14+ positive pulmonary sar-
omatoid carcinoma has recently been initiated in China (Table 2)
45].
.2.4. AMG-337
AMG337 (Amgen, Nanbio) is another highly selective, orally
vailable ATP-competitive MET  inhibitor [58]. In a phase 1/2 trial
f esophageal, gastro-esophageal junction, and gastric carcinoma,
MG337 demonstrated an impressive ORR of 62% (8/13) in a
ubset of patients that harbored high MET  ampliﬁcation, indi-
ating that it is a bonda ﬁde oral MET  inhibitor [59]. AMG337
as also been shown in vitro to inhibit migration, invasion, and
nchorage-independent growth in gastric cell lines harboring
ETex14 deletion that have been stimulated by puriﬁed HGF [60].
urrently there are no clinical trials investigating the activity of
MG337 against METex14+ NSCLC [45,53].
.3. Type II inhibitors
.3.1. Cabozantinib (Cometriq, XL184)
Cabozantinib (XL184, Cometriq; Elexis) is an oral, type II MET
nhibitor, effective against MET. Cabozantinib is multi-targeted, and
xhibits activity against other kinases, including vascular endothe-
ial growth factor receptor 2 (VEGFR2), KIT, RET, and AXL. Preclinical
tudies have demonstrated inhibition of both MET and VEGFR2
hosphorylation, and dose-dependent inhibition of tumor growth
n a variety of mouse models, including lung [61].
Cabozantinib was approved for medullary thyroid cancer in
012 [62]. Cabozantinib demonstrated modest single-agent activ-
ty in a phase 2 trial in patients with metastatic NSCLC (ORR
0%) [63]. In patients with EGFR-mutated NSCLC with resistance
o EGFR TKIs, clinical activity was observed following treatment
ith cabozantinib and erlotinib; however, it should be noted that
ET  ampliﬁcation was not detected in the study population [64]. A Cancer 103 (2017) 27–37
recent publication described a patient with lung adenocarcinoma
with EGFR+/MET  ampliﬁcation who  developed a new mutation in
MET (D1228V) after progression on savolitinib and osimertinib,
and subsequently responded to treatment with cabozantinib and
erlotinib [65]. One case series reported a METex14+ NSCLC patient
with concurrent MET ampliﬁcation who achieved a complete
response to cabozantinib [21]. Currently there is an investigator-
initiated, single institution phase 2 study focusing on patients with
MET-mutated NSCLC, among other actionable driver mutations, in
NSCLC (Table 2) [45].
3.3.2. Glesatinib (MGCD265)
Glesatinib (MGCD265; Mirati Therapeutics) is a type II oral
inhibitor, with activity against MET, VEGFR1/2/3, RON, and TIE-
2. Preclinical antitumor activity was  demonstrated in NSCLC
xenograft models, including in an EGFR TKI-resistant model, when
combined with erlotinib [66]. Subsequent studies in a gastric can-
cer xenograft model revealed that, in addition to the typically
reported cellular activities, glesatinib in combination with erlotinib
disrupted the glycolysis pathway, suggesting a novel mechanism of
action for this drug [67].
In an ongoing phase 1 study in patients with MET+ or
AXL-rearranged advanced solid tumors, glesatinib demonstrated
preliminary single-agent activity, with all three patients with
MET dysregulated NSCLC (two with METex14 alterations and one
with increased GCN) showing signiﬁcant tumor regression at the
ﬁrst assessment [68]. A phase 2 study is currently recruiting
patients with MET-dysregulated (mutated or ampliﬁed) advanced
or metastatic NSCLC (Table 2) [69].
3.3.3. Merestinib (LY2801653)
Merestinib (Lilly, Inc) is a multi-targeted TKI that can inhibit
MET, RON, AXL, MER  receptor tyrosine kinase (MERTK), TIE-2, TIE-1,
ROS1, and discoidin domain receptor tyrosine kinase 1 (DDR1) [70].
The in vitro IC50 of merestinib against MET  is 4.7 nM and the cell-
based IC50 is 35–52 nM,  depending on the cell lines utilized [70].
Treatment with merestinib inhibited the constitutive activation of
MET signaling and resulted in inhibition of NCI-H441 cell prolif-
eration, anchorage-independent growth, migration, and invasion.
Additionally, merestinib inhibited orthopedic H441 primary tumor
growth or metastasis and resulted in longer survival of mice bearing
the H441 orthopedic transplant compared with vehicle injection
[71]. In the H1993 NSCLC cell line, which harbors MET  ampliﬁca-
tion and also overexpression of RON, merestinib was superior to
crizotinib in terms of cellular growth inhibitory activity (9.28 nM
versus 45.4 nM,  respectively) [72].
A phase 2 study has recently been initiated that includes a cohort
of patients with METex14-mutated NSCLC (Table 2) [45].
4. Clinicopathologic characteristics of METex14+ NSCLC
patients (the Unknown)
Although there have been many reports on the clinicopatho-
logic characteristics of METex14+ NSCLC patients (Table 1), much
remains to be discovered. Firstly, the prevalence of brain metastasis
at the time of diagnosis of METex14+ NSCLC patients is unknown.
Even more importantly, the prevalence of central nervous sys-
tem (CNS) progression from MET  TKIs is unknown. If the natural
history of METex14+ NSCLC disease mirrors that of ALK+ NSCLC
[73], then progression in the CNS will be a signiﬁcant therapeu-
tic challenge to MET-targeted therapy, and the ability of MET  TKIs
to penetrate the CNS will be of paramount importance. Prelimi-
nary CNS activity of cabozantinib in a METex14+ NSCLC patient has
been observed [74]. Secondly, while it is generally established that
MET ampliﬁcation is a poor prognostic factor in NSCLC [73,75–77],
the prognostic signiﬁcance of METex14 alterations in NSCLC is
/ Lung
u
t
t
[
ﬁ
a
a
i
a
a
i
r
i
5
(
o
o
s
T
n
[
[
a
M
i
i
t
c
t
5
a
t
F
t
r
T
p
M
t
i
t
p
m
t
m
c
5
M
N
p
t
p
m
o
m
a
oT. Reungwetwattana et al. 
nknown. Thirdly, Schrock and colleagues have demonstrated that
umors with METex14+ alterations with concurrent MET ampliﬁca-
ion harbored a signiﬁcantly higher total mutational burden (TMB)
31]. It remains to be determined whether concurrent MET ampli-
cation modulates the response to MET  TKIs, as this molecular
lteration could affect the efﬁcacy of MET  TKIs if it is not properly
ccounted for. Fourthly, Schrock and colleagues also reported a high
ncidence of concurrent MDM2  ampliﬁcation [31]. MDM2  encodes
n E3 ubiquitin-protein ligase, and whether MDM2 ampliﬁcation is
 response to the absence of an E3 ubiquitin-protein ligase bind-
ng site in the METex14 altered protein, or whether it has another
ole in METex14+ NSCLC, such as resistance to TKIs, remains to be
nvestigated [78].
. Potential strategies to overcome resistance to MET TKIs
the Inevitable)
Resistance to targeted therapy with a single agent TKI invariably
ccurs (Fig. 2). The tight binding of the MET  TKIs to the ATP-pocket
f MET  RTK is facilitated by several hydrophobic interactions at
everal speciﬁc amino acids. In vitro mutagenesis assays with MET
KIs in MET-dependent tumors have identiﬁed several predomi-
ant resistance mutations against type I inhibitors (Y1230, D1228)
79,80] and several minor resistance mutations (F1200, V1155)
80]. Indeed, acquired crizotinib resistance mutations, MET  D1228N
nd MET  Y1230C, have recently been described in patients with
ETex14+ NSCLC refractory to crizotinib [81,82]. Residue D1228 is
mportant to stabilize the orientation of the activation loop in the
nactive autoinhibitory conformation of MET, and D1228N muta-
ions have been shown to switch the turnover number (Kcat [s−1]) of
rizotinib from 0.27 ± 0.05 (inactivated MET  [unphosphorylated])
o 11.3 ± 3.0 (activated [phosphorylated]) [83].
.1. Switching from type I to type II inhibitors or vice versa for
cquired resistance mutations
Given that type I inhibitors require stacking with Y1230 to bind
o MET, mutations in Y1230 abolish the binding of type I MET  TKIs.
or example, the IC50 of AMG337 against wild-type MET  is 1 nM,  but
he IC50s against Y1230H and D1228H are 1077 nM and >4000 nM,
espectively [58]. Switching from a type I MET  TKI to type II MET
KI may  overcome this group of resistance mutations; for exam-
le, the IC50s of merestinib against wild-type Y1230C and D1228N
ET  are 42 nM,  54 nM,  and 111 nM,  respectively [70]. Clinical trials
hat allow switching from type I inhibitors (the predominant TKIs
n clinical trial) to type II inhibitors will have to be conducted to
horoughly test this hypothesis, but data from one case study is sup-
ortive: a patient with lung adenocarcinoma and a D1228H point
utation responded to cabozantinib after progression on savoli-
inib [65]. Additionally, the ability to detect the acquired resistance
echanism will be important to ensure the success of these “non-
ross resistant” trials.
.2. “Total” MET  signaling axis blockade
An important difference between RTK-rearranged NSCLC and
ETex14+ NSCLC is that the ligand binding domain of METex14+
SCLC is intact, and ligand-mediated activation of the MET  receptor
rotein is ongoing. Therefore, one potential mechanism of resis-
ance is the upregulation of HGF, which can potentially increase the
ercentage of MET  receptors in the active (phosphorylated) confor-
ation, increasing the Michaelis constant (Km, the concentration
f substrate that permits the enzyme to achieve half the Vmax, the
aximum rate of the reaction) of ATP inhibitors, and essentially
bolishing the binding of type II inhibitors to MET  [37]. Thus, to
vercome or delay the emergence of resistance to MET TKIs, it may Cancer 103 (2017) 27–37 33
be advisable to combine MET  TKIs with antibodies against HGF, or
antibodies that block ligand binding to or dimerization of the MET
receptor. This is similar to the design rationale of the 4th generation
EGFR TKIs [84].
5.2.1. Combination with antibodies against MET
5.2.1.1. Emibetuzumab (LY2875358). Emibetuzumab (LY2875358;
Lilly) is a humanized, bivalent, IgG4 mAb, designed to block both
ligand-dependent and ligand-independent MET signaling (binding
afﬁnity 0.8 pM)  [85]. It induces internalization and degradation of
MET, inhibiting proliferation of tumor cells with MET  ampliﬁcation
and providing antitumor activity in xenograft models of NSCLC [85].
Preliminary, but limited, single-agent clinical activity was observed
in a phase I trial in patients with MET+ (IHC ≥2+) solid tumors,
including NSCLC [86].
5.2.1.2. ABT-700. ABT-700 (hz224G11; AbbVie) is a humanized,
IgG1 mAb  with nanomolar afﬁnity for human MET. It exhibited pre-
clinical activity in cell lines, inhibiting HGF binding and subsequent
MET  phosphorylation, and also induced apoptosis in gastric cancer
xenografts [87]. The safety and preliminary efﬁcacy of ABT-700 is
currently being investigated in a phase 1 trial in patients with MET
dysregulated solid tumors [45].
5.2.2. Combination with antibodies against HGF
5.2.2.1. Ficlatuzumab. Ficlatuzumab (AV-299; Aveo) is a human-
ized IgG1 mAb, capable of binding HGF with high afﬁnity
and inhibiting activity at sub-nanomolar concentrations [88]. In
a phase 2 study in Asian patients with NSCLC, ﬁclatuzumab
in combination with geﬁtinib showed preliminary efﬁcacy in
the EGFR-mutated, low-MET population [89]. Clinical develop-
ment is ongoing, including a proof-of-concept study (FOCAL) of
ﬁclatuzumab in combination with erlotinib in patients with EGFR-
mutant NSCLC selected using BDX004, a serum-based proteomic
companion diagnostic test [45,90].
5.2.3. Combination with antibody–drug conjugates
5.2.3.1. ABBV-399. Antibody–drug conjugates represent a novel
class of drugs that utilize targeted antibodies to deliver cytotoxic
agents directly to tumor cells. ABBV-399 (AbbVie) is a ﬁrst-in-class
conjugate of a MET  Ab, ABT-700, and an antimicrotubule agent,
monomethyl auristatin E. Preliminary analysis from a phase 1 study
in patients (N = 45) with metastatic solid tumors that included
an expansion cohort of 10 patients with MET+ (IHC ≥2+) NSCLC
reported promising antitumor activity in these MET+ patients (30%
response) [91]. Given that the major sequela of METex14 deletion is
persistence of the MET  protein, this molecular subgroup of NSCLC
is a good target for ABBV-399.
5.3. Combination with immunotherapy
Immunotherapy utilizing anti-programmed cell death protein 1
(anti-PD-1) antibodies has been approved in the US for platinum-
refractory NSCLC based on signiﬁcant overall survival beneﬁt
over single-agent docetaxel [92–94]. Rivzi and colleagues have
reported that mutational load is closely related to response to
pembrolizumab [95]. Tumor mutational load can serve as a surro-
gate marker for the reservoir of neoantigens, with higher mutation
load corresponding to higher reservoir of neoantigens. The aver-
age TMB  in METex14+ NSCLC patients was 6.9 mutations/Mb
(range 0–197.9), which is slightly lower than the overall average
of 10.7 mutations/Mb for all lung cancer cases [31], but higher
than the average TMB  for EGFR-mutated (mean, 4.5) and ALK+
NSCLC (mean, 2.8) patients [96]. Gainor and colleagues reported
that for EGFR-mutated and ALK+ NSCLC patients, the incidence of
co-expression of PD-L1 is low, as is response to anti-PD-L1/PD-1
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Fig. 2. Mechanisms of resistance to single-agent MET  TKIs in the ligand-dependent setting, and potential strategies to overcome this resistance. (A) HGF-mediated MET
signaling can be blocked by TKI binding. (B) TKI resistance can result from mutation of MET; this can be overcome by use of a different inhibitor. (C) TKI resistance can result
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GF: hepatocyte growth factor; TKI: tyrosine kinase inhibitor.
herapy [97]. While the expression level of PD-L1 among patients
ith METex14+ NSCLC is currently unknown, a higher average
MB  among METex14+ NSCLC patients than EGFR+ or ALK+ NSCLC
atients, especially among the MET  ampliﬁed subgroup, would sug-
est that the combination of MET  TKIs and immunotherapy may  be
uccessful.
. Conclusions
Only two years ago, ampliﬁcation of MET  in NSCLC was postu-
ated to be the target that would lead to the eventual regulatory
pproval of MET  TKIs [98]. As the incidence of true de novo MET
mpliﬁcation remains low (0.8%) and the incidence of MET ampliﬁ-
ation as a resistance mechanism to EGFR TKIs is only 5%, the roadnal antibodies.
to regulatory approval of MET  TKIs seemed uncertain [98]. There
has since been renewed interest in METex14 alterations in NSCLC,
with the prevalence closer to 3%, and reports of responses to MET
TKIs. Dedicated clinical trials with MET  TKIs in METex14+ NSCLC
are underway, which are likely to lead to the eventual approvals of
MET  TKIs.
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